Klemens Schuette Appointed Managing Director at Ecron Acunova Germany (EAG)

Emirates PharmaAdvertisement

D A Prasanna, Founder and Chairman of Ecron Acunova group (EA), is pleased to announce the appointment of Klemens Schuette as Managing Director Germany. Mr Schuette joins the Managing Director of EA Germany & CEO Europe, Dr Klaus Wiedey, by assuming overall responsibility for all operational aspects of the German operations.

Mr Schuette has more than 20 years experience in the pharmaceutical and CRO industry. Before starting at EAG, Mr Schuette was Managing Director of Ergomed in Germany & UK, and COO of the Ergomed group. Prior to that he was board member of the British site management organisation Intercern and Director of Clinical Operations at ASTA Medica. Mr Schuette holds a masters degree in biology/biochemistry (1988) from the University of Konstanz, Germany.

Speaking on the appointment, D A Prasanna said, “Mr Schuette unifies extensive professional experience in clinical research services and management of day-to-day business. With his knowledge and interpersonal skills Mr Schuette will support EAG to grow to its next level of achievements.”

On his appointment, Mr Schuette said, “I am convinced that EA with its highly qualified, committed and enthusiastic team has an amazing potential and outstanding opportunities ahead. I highly appreciate the opportunity to lead EAG to further heights of success.”

EA is an expert CRO with 25 years of track record. It offers full-service clinical research including clinical operations, data management, biostatistics, pharmacovigilance, PK/PD services and central lab to pharma, biotech, medical device, nutrition and diagnostic companies. EA covers 19Western & Eastern European countries as well as 9 South Asian & South East Asian countries. EA operates each region as a priority market with European HQ in Frankfurt, Asian HQ in Bangalore, and US HQ at Princeton. With a team of 358 professionals including 76 MDs, PhDs and alike, EA is reputed to accelerate pharma time-to-market cost effectively.

 

 

 

Emirates PharmaAdvertisement